Botulinum Chimera Compositions for Axonal Regenerative Therapy During Spinal Cord Injury
The present invention relates to the isolation of polypeptides derived from the Clostridium botulinum neurotoxin and the use thereof as treatment for neuronal injury such as spinal cord injury. Botulinum neurotoxin binds to neural cells and are translocated into the cytosol and therefore is useful as a target specific therapeutic delivery system. Non-toxic botulinum toxin may be created by light chain mutagenesis and/or removal of the endopeptidase domain.
1 . A composition comprising a chimeric protein comprising a C3E-exoenzyme protein and a non-toxic neurotoxin heavy chain.
2 . The composition of claim 1 , wherein said neurotoxin heavy chain comprises a Clostridium botulinum neurotoxin heavy chain.
3 . The composition of claim 1 , wherein said chimeric protein further comprises neurotoxin light chain.
4 . The composition of claim 3 , wherein said neurotoxin light chain lacks an endopeptidase region.
5 . The composition of claim 3 , wherein said neurotoxin light chain comprises at least one mutation.
6 . The composition of claim 3 , wherein said neurotoxin light chain comprises at least two mutations.
7 . The composition of claim 5 , wherein said at least one mutation is selected from at least one of the group consisting of H223M, H227Q, E224A or E262A.
8 . The composition of claim 1 , wherein said C3E-exoenzyme protein is a Clostridium botulinum C3E-exoenzyme protein.
9 . The composition of claim 1 , wherein said C3E protein and said heavy chain are linked by a disulfide bridge.
10 . The composition of claim 1 , wherein said C3E protein is attached to the light chain.
11 . A method, comprising:
a) providing;
i) a patient having a nerve tissue injury;
ii) a composition comprising a chimeric protein comprising a C3E protein and a non-toxic neurotoxin heavy chain;
b) administering said composition to said patient wherein said nerve injury is at least partially regenerated.
12 . The method of claim 11 , wherein said nerve tissue injury comprises a spinal cord injury.
13 . The method of claim 11 , wherein said administering is selected from at least one of the group consisting of topical, intramuscular, intraspinal and intrathecal.
14 . The method of claim 11 , wherein said neurotoxin heavy chain comprises a Clostridium botulinum neurotoxin heavy chain.
15 . The method of claim 11 , wherein said chimeric protein further comprises neurotoxin light chain.
16 . The method of claim 15 , wherein said neurotoxin light chain lacks an endopeptidase region.
17 . The method of claim 15 , wherein said neurotoxin light chain comprises at least one mutation.
18 . The method of claim 15 , wherein said neurotoxin light chain comprises at least two mutations.
19 . The method of claim 17 , wherein said at least one mutation is selected from at least one of the group consisting of H223M, H227Q, E224A and E262A.
20 . The method of claim 11 , wherein said C3E-exoenzyme protein is a Clostridium botulinum C3E-exoenzyme protein.
21 . The method of claim 11 , wherein said C3E protein and the heavy chain are linked by a disulfide bridge.
22 . The method of claim 15 , wherein said C3E protein is attached to said neurotoxin light chain.